Valuation Trading Multiples & Precedent Transactions: Diagnostic Imaging and Clinical Diagnostics Companies
Valuation benchmarks for Diagnostic Imaging and Clinical Diagnostics Companies. Access public trading comps, EV/EBITDA acquisition multiples, and private market data for pitch books and valuation analysis.
1.1 - Diagnostic Imaging and Clinical Diagnostics Companies Market Context & Valuation Drivers
Companies in this public trading comparables group deliver diagnostic imaging devices, contrast agents, and provider-based imaging and laboratory services. Business models span capital equipment sales, consumables, and fee-for-service testing with payer reimbursement. They are comparable because revenues are driven by procedure volumes, installed base penetration, clinical accuracy, and referral networks, creating recurring utilization and consumables demand, with similar regulatory, compliance, and reimbursement dynamics across imaging and diagnostics end markets.
Typical offerings include ultrasound systems, MRI, CT, PET/CT, and X-ray modalities; high-definition endoscopy platforms; radiopharmaceuticals and ultrasound contrast agents; clinical laboratory testing and pathology services; and multi-site imaging center operations with scheduling, patient intake, and reporting workflows. Many vendors provide service contracts, software integration, PACS connectivity, and home sample collection, enabling recurring revenue streams through consumable usage, maintenance, and reimbursable procedures across hospital and outpatient care settings.
Primary customers include hospitals and health systems, outpatient imaging centers, and diagnostic laboratories serving specialist and primary care referrals. Key valuation benchmarks include procedure and test volumes per site, same-center revenue growth, average selling prices and mix for equipment and agents, reimbursement rates by modality, recurring revenue penetration, EBITDA margins, and utilization of installed assets. Stable referral networks and high retention underpin durable cash flows and defendable market positions.
2. Valuation Analysis: Public Trading Comps & Multiples for Diagnostic Imaging and Clinical Diagnostics Companies companies
2.1 - Public Peer Groups & Median Valuation Multiples for Diagnostic Imaging and Clinical Diagnostics Companies sector
Comparable group 1: Diagnostic Imaging and Clinical Diagnostics Companies
SonoScape
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of medical imaging and endoscopy systems offering advanced ultrasound and high-definition endoscopic diagnosis solutions, focusing on enhancing healthcare equality through innovative and minimally invasive medical technologies.
- Key Products:
- Ultrasound Systems: High-performance trolley and portable systems for diverse medical use
- Endoscopy Systems: High-definition solutions for effective endoscopic diagnosis and treatments
- Cardiovascular Intervention: Tools designed for precise cardiovascular procedures
- Veterinary Equipment: Tailored imaging solutions for animal healthcare
- In-Vitro Diagnostic Devices: Equipment supporting various laboratory diagnostic needs
Dr. Lal PathLabs
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of diagnostic and healthcare tests focusing on blood, urine, and other pathology services; offering online booking and home collection.
- Key Products:
- Blood Tests: Comprehensive analysis of blood for various health markers
- Urine Tests: Diagnostics of urine to detect potential health issues
- Pathology Services: Tests on tissue samples for disease detection and monitoring
- Home Collection: Convenient collection of samples from home for diagnostics
- Online Booking: Easy and efficient booking of healthcare tests online.